Podcasts about treatments

In this episode of Quah (Q & A), Sal, Adam & Justin coach four Pump Heads via Zoom. Mind Pump Fit Tip: 7 natural ways to crush chronic inflammation and pain. (1:32) The benefits of regular napping. (21:50) Overactive bladder syndrome. (28:25) Green tea consumption = higher testosterone. (35:48) If you were stranded on an island, would you rather be by yourself or with your worst enemy? (36:40) Adam's Best Buy fiasco. (43:11) Sodium, low-carb diets, and performance. (47:42) Previewing Sal's upcoming YouTube series. (49:54) Mind Pump is looking for trainers. Apply today! (53:24) #ListenerLive question #1 – Is MAPS Muscle Mommy the right program for me being 14 months post-partum? If I'm only lifting 3 days a week and not looking to do extra work from home, are the trigger sessions necessary? (54:10) #ListenerLive question #2 – How can someone in a cut still feel confident about their progress when the scale isn't moving? (1:10:22) #ListenerLive question #3 – How would you go about actively inspiring reform and rebuilding a community for people who are so set in their ways? (1:18:57) #ListenerLive question #4 – Is there anything I can do to build a more resilient CNS or recover better so I don't need those rest weeks as often? (1:36:20) Related Links/Products Mentioned Ask a question to Mind Pump, live! Email: live@mindpumpmedia.com Visit NED for an exclusive offer for Mind Pump listeners! ** Code MINDPUMP at checkout for 20% off ** Get your free Sample Pack with any “drink mix” purchase! Find your favorite LMNT flavor, or share it with a friend. Try LMNT risk-free. If you don't like it, give it away to a salty friend and we'll give you your money back, no questions asked! Visit DrinkLMNT.com/MindPump June Special: Shredded Summer Bundle or Bikini Bundle 50% off! ** Code JUNE50 at checkout ** The effects of curcumin-containing supplements on biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomized controlled trials Importance of maintaining a low omega–6/omega–3 ratio for reducing inflammation Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis Visit Organifi for the exclusive offer for Mind Pump listeners! **Promo code MINDPUMP at checkout for 20% off** Regular Napping Linked to Increased Brain Size Mirabegron in the Treatment of Overactive Bladder Why Green Tea Could Be Your New Secret Weapon for More Testosterone TableTopics Dinner Party Question Card Game - 135 Entertaining Conversation Starter Cards for Dinner Table with Adult Friends, Getting to Know You Game. Mind Pump Personal Training – Apply today! Visit Butcher Box for this month's exclusive Mind Pump offer!  ** Available for a limited time, a curated box pre-filled with Mind Pump's favorite cuts — no guesswork! ButcherBox members who sign up through Mind Pump will receive: $20 OFF their first box, Free chicken breast, ground beef, OR salmon in every box for a whole year! ** 10 Ways To Rebuild MUSCLE & Train SAFELY After Having A Baby | Mind Pump 1882 Mind Pump #2320: Throw Away the Scale! Mind Pump #2420: Get Energized: The Real Reasons You're Always Tired & Lazy! Mind Pump Podcast – YouTube Mind Pump Free Resources People Mentioned Jay Campbell (@jaycampbell333) Instagram Dr. Stephen Cabral (@stephencabral) Instagram  

This week on The Treatment, Elvis Mitchell speaks with Emmy winning actress Mariska Hargitay about her record-breaking run as Olivia Benson on Law & Order: Special Victims Unit and her new (and very personal) HBO documentary My Mom Jayne. Then, screenwriter Scott Z Burns stops by to talk about his new Audible Podcast series What Could Go Wrong? And on The Treat, Freaky Tales co-director Ryan Fleck hails a film that's a warm slice of Big Apple life.

In his weekly clinical update, Dr. Griffin with Vincent Racaniello are alarmed at how RFK is breaking his promise of not altering vaccine policies, and nonexistent data and studies are used by members of the ACIP to make changes to immunization practices in the absence of a CDC director, justification for not honoring the US commitment to GAVI and global public policies including support of routine childhood immunizations, placing millions of children at risk for the return of vaccine preventable diseases including polio outbreaks in Pappa New Guinea and increased circulation of wildtype type 1 poliovirus, before Dr. Griffin reviews recent statistics on RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, approval of Merck's anti-RSV mRNA monoclonal antibody, whether or not the NB.1.8.1 should be included in the fall 2025 vaccines, immunization recommendations for COVID-19 vaccines, where to find PEMGARDA, changes in COVID mRNA vaccine labeling and reframing of the science around the vaccine, provides information for Columbia University Irving Medical Center's long COVID treatment center, where to go for answers to your long COVID questions, and contacting your federal government representative to stop the assault on science and biomedical research Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Jake Scott (Stanford University) Vaccine Randomized control trials (Bradspellberg.com) Vaccine RCT spreadsheet aims to show the data, dispel myths about vaccines  (CIDRAP) Vaccines-rcts (Bradspellberg.com) CDC's upcoming vaccine advisory meeting set up to sow distrust in vaccines (CIDRAP) Next ACIP meeting (CDC: ACIP) June meeting: MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) (CDC: ACIP agenda) Robert F Berman, PhD (UC Davis Health: Department of Neurological Surgery) Transparency = nonexistent data: CDC advisers appears to cite nonexistent study to support claims about risk of vaccine preservative (CNN) A C.D.C. Committee Just Voted Against Flu Shots With This Preservative. Is It Safe? (NY Times) CDC vaccine advisory committee to review long-approved immunizations (STAT News) Newly appointed CDC vaccine advisory committee holds first meeting, stirs more controversy (CIDRAP) FDA approves clesrovimab to protect infants during first RSV season (Contemporary Pediatrics) ACIP updates: Committee recommends clesrovimab for RSV, reaffirms routine influenza vaccination (Contemporary Pediatrics) Susan Monarez (Wikipedia) Robert F Kennedy Jr (Wikipedia) Centers for Disease Control and Prevention (Wikipedia) Who is in charge at the CDC (CDC: About CDC) Do children REALLY need to be vaccinated? (Wall Street Journal) U.S. Adults' Views on Routine Childhood Vaccination (Harvard Opinion Research Program) RFK Jr. declares US withdrawal from GAVI (YouTube) Kennedy Withdraws U.S. Funding Pledge to International Vaccine Agency (NY Times) Millions of children at risk as global vaccine rates fall (Guardian) Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030 (LANCET) Polio this week: 47 WPV1 positive environmental samples this week! (GPEI) H5 bird flu: current situation (CDC: Avian Influenza) Cambodia logs fifth death from H5N1 avian flu as USDA weighs poultry vaccination (CIDRAP) Cambodia reports 6th H5N1 bird flu case this year(BNO News) USDA develops potential plan to vaccinate poultry for bird flu (Reuters) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Weekly measles and rubella monitoring (Government of Canada) Measles vaccine recommendations from NYP (jpg) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Measles (CDC: Measles Rubeola) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) FDA-CDC-DOD: 2025-2046 influenza vaccine composition (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Novel Drug Approvals for 2025 (FDA) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (biRxiV) Episode 184: Fool's Gold: Reframing the Science…..reframing? (Apple Podcasts: Osterholm Update) Children with Post COVID-19 Multisystem Inflammatory Syndrome Display Unique Pathophysiological Metabolic Phenotypes (Journal of Proteome Research) FDA COVID mRNA vaccine labeling update (FDA) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Steroids,dexamethasone at the right time (OFID) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Stellate Ganglion Block for the Treatment of COVID-19−Induced Parosmia (JAMA Otolaryngology-Head& Neck Surgery) Reaching out to US house representative Letters read on TWiV 1230 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Send Us Your Questions & Feedback!EPISODE SUMMARYYou might think a heavy metal concert is just loud music and flashing lights. But for me, Roger Magalhães, it became an unexpected masterclass in business, branding, and human connection. This episode pulls back the curtain on the raw, unfiltered lessons I learned from the mosh pit at a Metallica show in Tampa, showing how they apply directly to your work in the window treatment industry.THE A-HA MOMENTJust like a perfectly tuned guitar riff can electrify a stadium, the right approach to your business can create an unforgettable experience for your clients. Many believe that delivering a product is enough, but Metallica showed me that it's about the entire sensory journey. We're going to dive into how their incredible stage presence, genuine fan engagement, and ability to evolve while staying true to themselves offer a powerful guide for your business.We'll explore why going the extra mile makes every client feel seen, creating undeniable loyalty. You'll also understand why humility and connection build the strongest relationships and drive referrals, much like a band connecting with its audience.THE BREAKDOWNThe Power of Presence: How to ensure every client feels seen and valued, turning standard jobs into loyal customers.Charisma Over Ego: Why genuine connection and humility are your greatest assets in building lasting relationships.Consistency + Reinvention: The art of staying relevant and true to your craft in a constantly shifting industry, just like a band evolving its sound without losing its identity.KEY TAKEAWAYSMy take on why you should never cut corners on quality – the details truly matter.How to be the Metallica of your market: bringing the fire, professionalism, and unexpected magic that keeps people talking and coming back.Hit play and let's get into this story! You'll see that sometimes, the best business lessons come from the most unexpected places.

In a week where world leaders met for a NATO summit in the Netherlands and a volcanic eruption in Indonesia disrupted flights, we’re going to be discussing some of the other stories, events and people that inspired The Week Junior team.See omnystudio.com/listener for privacy information.

New treatment options are here for the hemophilia community! Learn more in Patrick's conversation with Craig Benson and our latest Gene therapy segment that focuses on the psychological impact of gene therapy. Plus, we share news about the Genentech and Spark integration.   Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more.   It's a Whole New World Gene Therapy Segment brought to you by CSL Behring, which now has a first-of-its-kind hemophilia B treatment. Visit BeyondHemB.com or download B SUPPORT wherever you get your apps for more information.   Segment is brought to you by Genentech: Visit www.hemashort.com to watch the short film. Show Notes:   Subscribe: The BloodStream Podcast   Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more.   Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on X/Twitter  BloodStream on Instagram BloodStream on LinkedIn BloodStream on TikTok  

Dr. Diwakar Davar and Dr. Jason Luke discuss novel agents in melanoma and other promising new data in the field of immunotherapy that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello. My name is Diwakar Davar, and I am welcoming you to the ASCO Daily News Podcast. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. Today, I'm joined by my colleague and good friend, Dr. Jason Luke. Dr. Luke is a professor of medicine. He is also the associate director of clinical research and the director of the Phase 1 IDDC Program at the University of Pittsburgh's Hillman Cancer Center. He and I are going to be discussing some key advancements in melanoma and skin cancers that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Jason, it is great to have you back on the podcast. Dr. Jason Luke: Thanks again so much for the opportunity, and I'm really looking forward to it. Dr. Diwakar Davar: Perfect. So we will go ahead and start talking a little bit about a couple of key abstracts in both the drug development immunotherapy space and the melanoma space. The first couple of abstracts, the first two, will cover melanoma. So, the first is LBA9500, which was essentially the primary results of RELATIVITY-098. RELATIVITY-098 was a phase 3 trial that compared nivolumab plus relatlimab in a fixed-dose combination against nivolumab alone for the adjuvant treatment of resected high-risk disease. Jason, do you want to maybe give us a brief context of what this is? Dr. Jason Luke: Yeah, it's great, thanks. So as almost all listeners, of course, will be aware, the use of anti–PD-1 immunotherapies really revolutionized melanoma oncology over the last 10 to 15 years. And it has become a standard of care in the adjuvant setting as well. But to review, in patients with stage III melanoma, treatment can be targeted towards BRAF with BRAF and MEK combination therapy, where that's relevant, or anti–PD-1 with nivolumab or pembrolizumab are a standard of care. And more recently, we've had the development of neoadjuvant approaches for palpable stage III disease. And in that space, if patients present, based on two different studies, either pembrolizumab or nivolumab plus ipilimumab can be given prior to surgery for somewhere in the 6- to 9-week range. And so all of these therapies have improved time-to-event endpoints, such as relapse-free or event-free survival. It's worth noting, however, that despite those advances, we've had a couple different trials now that have actually failed in this adjuvant setting, most high profile being the CheckMate-915 study, which looked at nivolumab plus ipilimumab and unfortunately was a negative study. So, with RELATIVITY-047, which was the trial of nivolumab plus relatlimab that showed an improvement in progression-free survival for metastatic disease, there's a lot of interest, and we've been awaiting these data for a long time for RELATIVITY-098, which, of course, is this adjuvant trial of LAG-3 blockade with relatlimab plus nivolumab. Dr. Diwakar Davar: Great. So with that, let's briefly discuss the trial design and the results. So this was a randomized, phase 3, blinded study, so double-blinded, so neither the investigators knew what the patients were getting, nor did the patients know what they were getting. The treatment investigational arm was nivolumab plus relatlimab in the fixed-dose combination. So that's the nivolumab standard fixed dose with relatlimab that was FDA approved in RELATIVITY-047. And the control arm was nivolumab by itself. The duration of treatment was 1 year. The patient population consisted of resected high-risk stage III or IV patients. The primary endpoint was investigator-assessed RFS. Stage and geography were the standard stratifying factors, and they were included, and most of the criteria were balanced across both arms. What we know at this point is that the 2-year RFS rate was 64% and 62% in the nivolumab and nivolumab-combination arms, respectively. The 2-year DMFS rate was similarly equivalent: 76% with nivolumab monotherapy, 73% with the combination. And similar to what you had talked about with CheckMate 915, unfortunately, the addition of LAG-3 did not appear to improve the RFS or DMFS compared to control in this patient population. So, tell us a little bit about your take on this and what do you think might be the reasons why this trial was negative? Dr. Jason Luke: It's really unfortunate that we have this negative phase 3 trial. There had been a lot of hope that the combination of nivolumab with relatlimab would be a better tolerated combination that increased the efficacy. So in the metastatic setting, we do have 047, the study that demonstrated nivolumab plus relatlimab, but now we have this negative trial in the adjuvant setting. And so as to why exactly, I think is a complicated scenario. You know, when we look at the hazard ratios for relapse-free survival, the primary endpoint, as well as the secondary endpoints for distant metastasis-free survival, we see that the hazard ratio is approximately 1. So there's basically no difference. And that really suggests that relatlimab in this setting had no impact whatsoever on therapeutic outcomes in terms of efficacy. Now, it's worth noting that there was a biomarker subanalysis that was presented in conjunction with these data that looked at some immunophenotyping, both from circulating T cells, CD8 T cells, as well as from the tumor microenvironment from patients who were treated, both in the previous metastatic trial, the RELATIVITY-047 study, and now in this adjuvant study in the RELATIVITY-098 study. And to briefly summarize those, what was identified was that T cells in advanced melanoma seemed to have higher expression levels of LAG-3 relative to T cells that are circulating in patients that are in the adjuvant setting. In addition to that, there was a suggestion that the magnitude of increase is greater in the advanced setting versus adjuvant. And the overall summary of this is that the suggested rationale for why this was a negative trial may have been that the target of LAG-3 is not expressed as highly in the adjuvant setting as it is in the metastatic setting. And so while the data that were presented, I think, support this kind of an idea, I am a little bit cautious that this is actually the reason for why the trial was negative, however. I would say we're not really sure yet as to why the trial was negative, but the fact that the hazard ratios for the major endpoints were essentially 1 suggests that there was no impact whatsoever from relatlimab. And this really makes one wonder whether or not building on anti–PD-1 in the adjuvant setting is feasible because anti–PD-1 works so well. You would think that even if the levels of LAG-3 expression were slightly different, you would have seen a trend in one direction or another by adding a second drug, relatlimab, in this scenario. So overall, I think it's an unfortunate circumstance that the trial is negative. Clearly there's going to be no role for relatlimab in the adjuvant setting. I think this really makes one wonder about the utility of LAG-3 blockade and how powerful it really can be. I think it's probably worth pointing out there's another adjuvant trial ongoing now of a different PD-1 and LAG-3 combination, and that's cemiplimab plus fianlimab, a LAG-3 antibody that's being dosed from another trial sponsor at a much higher dose, and perhaps that may make some level of difference. But certainly, these are unfortunate results that will not advance the field beyond where we were at already. Dr. Diwakar Davar: And to your point about third-generation checkpoint factors that were negative, I guess it's probably worth noting that a trial that you were involved with, KeyVibe-010, that evaluated the PD-1 TIGIT co-formulation of vibostolimab, MK-4280A, was also, unfortunately, similarly negative. So, to your point, it's not clear that all these third-generation receptors are necessarily going to have the same impact in the adjuvant setting, even if they, you know, for example, like TIGIT, and they sometimes may not even have an effect at all in the advanced cancer setting. So, we'll see what the HARMONY phase 3 trial, that's the Regeneron cemiplimab/fianlimab versus pembrolizumab control with cemiplimab with fianlimab at two different doses, we'll see how that reads out. But certainly, as you've said, LAG-3 does not, unfortunately, appear to have an impact in the adjuvant setting. So let's move on to LBA9501. This is the primary analysis of EORTC-2139-MG or the Columbus-AD trial. This was a randomized trial of encorafenib and binimetinib, which we will abbreviate as enco-bini going forward, compared to placebo in high-risk stage II setting in melanoma in patients with BRAF V600E or K mutant disease. So Jason, you know, you happen to know one or two things about the resected stage II setting, so maybe contextualize the stage II setting for us based on the trials that you've led, KEYNOTE-716, as well as CheckMate-76K, set us up to talk about Columbus-AD. Dr. Jason Luke: Thanks for that introduction, and certainly stage II disease has been something I've worked a lot on. The rationale for that has been that building off of the activity of anti–PD-1 in metastatic melanoma and then seeing the activity in stage III, like we just talked about, it was a curious circumstance that dating back about 7 to 8 years ago, there was no availability to use anti–PD-1 for high-risk stage II patients, even though the risk of recurrence and death from melanoma in the context of stage IIB and IIC melanoma is in fact similar or actually higher than in stage IIIA or IIIB, where anti–PD-1 was approved. And in that context, a couple of different trials that you alluded to, the Keynote-716 study that I led, as well as the CheckMate 76K trial, evaluated pembrolizumab and nivolumab, respectively, showing an improvement in relapse-free and distant metastasis-free survival, and both of those agents have subsequently been approved for use in the adjuvant setting by the US FDA as well as the European Medicines Agency.  So bringing then to this abstract, throughout melanoma oncology, we've seen that the impact of anti–PD-1 immunotherapy versus BRAF and MEK-targeted therapy have had very similar outcomes on a sort of comparison basis, both in frontline metastatic and then in adjuvant setting. So it was a totally reasonable question to ask: Could we use adjuvant BRAF and MEK inhibitor therapy? And I think all of us expected the answer would be yes. As we get into the discussion of the trial, I think the unfortunate circumstance was that the timing of this clinical trial being delayed somewhat, unfortunately, made it very difficult to accrue the trial, and so we're going to have to try to read through the tea leaves sort of, based on only a partially complete data set. Dr. Diwakar Davar: So, in terms of the results, they wanted to enroll 815 patients, they only enrolled 110. The RFS and DMFS were marginally improved in the treatment arm but certainly not significantly, which is not surprising because the trial had only accrued 16% to 18% of its complete accrual. As such, we really can't abstract from the stage III COMBI-AD data to stage II patients. And certainly in this setting, one would argue that the primary treatment options certainly remain either anti–PD-1 monotherapy, either with pembrolizumab or nivolumab, based on 716 or 76K, or potentially active surveillance for the patients who are not inclined to get treated.  Can you tell us a little bit about how you foresee drug development going forward in this space because, you know, for example, with HARMONY, certainly IIC disease is a part of HARMONY. We will know at least a little bit about that in this space. So what do you think about the stage IIB/C patient population? Is this a patient population in which future combinations are going to be helpful, and how would you think about where we can go forward from here? Dr. Jason Luke: It is an unfortunate circumstance that this trial could not be accrued at the pace that was necessary. I think all of us believe that the results would have been positive if they'd been able to accrue the trial. In the preliminary data set that they did disclose of that 110 patients, you know, it's clear there is a difference at a, you know, a landmark at a year. They showed a 16% difference, and that would be in line with what has been seen in stage III. And so, you know, I think it's really kind of too bad. There's really going to be no regulatory approach for this consideration. So using BRAF and MEK inhibition in stage II is not going to be part of standard practice moving into the future. To your point, though, about where will the field go? I think what we're already realizing is that in the adjuvant setting, we're really overtreating the total population. And so beyond merely staging by AJCC criteria, we need to move to biomarker selection to help inform which patients truly need the treatment. And in that regard, I don't think we've crystallized together as a field as yet, but the kinds of things that people are thinking about are the integration of molecular biomarkers like ctDNA. When it's positive, it can be very helpful, but in melanoma, we found that, unfortunately, the rates are quite low, you know, in the 10% to 15% range in the adjuvant setting. So then another consideration would be factors in the primary tumor, such as gene expression profiling or other considerations.  And so I think the future of adjuvant clinical trials will be an integration of both the standard AJCC staging system as well as some kind of overlaid molecular biomarker that helps to enrich for a higher-risk population of patients because on a high level, when you abstract out, it's just clearly the case that we're rather substantially overtreating the totality of the population, especially given that in all of our adjuvant studies to date for anti–PD-1, we have not yet shown that there's an overall survival advantage. And so some are even arguing perhaps we should even reserve treatment until patients progress. I think that's a complicated subject, and standard of care at this point is to offer adjuvant therapy, but certainly a lot more to do because many patients, you know, unfortunately, still do progress and move on to metastatic disease. Dr. Diwakar Davar: Let's transition to Abstract 2508. So we're moving on from the melanoma to the novel immunotherapy abstracts. And this is a very, very, very fascinating drug. It's IMA203. So Abstract 2508 is a phase 1 clinical update of IMA203. IMA203 is an autologous TCR-T construct targeting PRAME in patients with heavily pretreated PD-1-refractory metastatic melanoma. So Jason, in the PD-1 and CTLA-4-refractory settings, treatment options are either autologous TIL, response rate, you know, ballpark 29% to 31%, oncolytic viral therapy, RP1 with nivolumab, ORR about 30-ish percent. So new options are needed. Can you tell us a little bit about IMA203? Perhaps tell us for the audience, what is the difference between a TCR-T and traditional autologous TIL? And a little bit about this drug, IMA203, and how it distinguishes itself from the competing TIL products in the landscape. Dr. Jason Luke: I'm extremely enthusiastic about IMA203. I think that it really has transformative potential based on these results and hopefully from the phase 3 trial that's open to accrual now. So, what is IMA203? We said it's a TCR-T cell product. So what that means is that T cells are removed from a patient, and then they can be transduced through various technologies, but inserted into those T cells, we can then add a T-cell receptor that's very specific to a single antigen, and in this case, it's PRAME. So that then is contrasted quite a bit from the TIL process, which includes a surgical resection of a tumor where T cells are removed, but they're not specific necessarily to the cancer, and they're grown up in the lab and then given to the patient. They're both adoptive cell transfer products, but they're very different. One is genetically modified, and the other one is not. And so the process for generating a TCR-T cell is that patients are required to have a new biomarker that some may not be familiar with, which is HLA profiling. So the T-cell receptor requires matching to the concomitant HLA for which the peptide is bound in. And so the classic one that is used in most oncology practices is A*02:01 because approximately 48% of Caucasians have A*02:01, and the frequency of HLA in other ethnicities starts to become highly variable. But in patients who are identified to have A*02:01 genotype, we can then remove blood via leukapheresis or an apheresis product, and then insert via lentiviral transduction this T-cell receptor targeting PRAME. Patients are then brought back to the hospital where they can receive lymphodepleting chemotherapy and then receive the reinfusion of the TCR-T cells. Again, in contrast with the TIL process, however, these T cells are extremely potent, and we do not need to give high-dose interleukin-2, which is administered in the context of TIL. Given that process, we have this clinical trial in front of us now, and at ASCO, the update was from the phase 1 study, which was looking at IMA203 in an efficacy population of melanoma patients who were refractory at checkpoint blockade and actually multiple lines of therapy. So here, there were 33 patients and a response rate of approximately 50% was observed in this population of patients, notably with a duration of response approximately a year in that treatment group. And I realize that these were heavily pretreated patients who had a range of very high-risk features. And approximately half the population had uveal melanoma, which people may be aware is a generally speaking more difficult-to-treat subtype of melanoma that metastasizes to the liver, which again has been a site of resistance to cancer immunotherapy. So these results are extremely promising. To summarize them from what I said, it's easier to make TCR-T cells because we can remove blood from the patient to transduce the T cells, and we don't have to put them through surgery. We can then infuse them, and based on these results, it looks like the response rate to IMA203 is a little bit more than double what we expect from lifileucel. And then, whereas with lifileucel or TILs, we have to give high-dose IL-2, here we do not have to give high-dose IL-2. And so that's pretty promising. And a clinical trial is ongoing now called the SUPREME phase 3 clinical trial, which is hoping to validate these results in a randomized global study. Dr. Diwakar Davar: Now, one thing that I wanted to go over with you, because you know this trial particularly well, is what you think of the likelihood of success, and then we'll talk a little bit about the trial design. But in your mind, do you think that this is a trial that has got a reasonable likelihood of success, maybe even a high likelihood of success? And maybe let's contextualize that to say an alternative trial, such as, for example, the TebeAM trial, which is essentially a T-cell bispecific targeting GP100. It's being compared against SOC, investigator's choice control, also in a similarly heavily pretreated patient population. Dr. Jason Luke: So both trials, I think, have a strong chance of success. They are very different kinds of agents. And so the CD3 bispecific that you referred to, tebentafusp, likely has an effect of delaying progression, which in patients with advanced disease could have a value that might manifest as overall survival. With TCR-T cells, by contrast, we see a very high response rate with some of the patients going into very durable long-term benefit. And so I do think that the SUPREME clinical trial has a very high chance of success. It will be the first clinical trial in solid tumor oncology randomizing patients to receive a cell therapy as compared with a standard of care. And within that standard of care control arm, TILs are allowed as a treatment. And so it will also be the first study that will compare TCR-T cells against TILs in a randomized phase 3. But going back to the data that we've seen in the phase 1 trial, what we observe is that the duration of response is really connected to the quality of the response, meaning if you have more than a 50% tumor shrinkage, those patients do very, very well. But even in patients who have less than 50% tumor shrinkage, the median progression-free survival right now is about 4.5 months. And again, as we think about trial design, standard of care options for patients who are in this situation are unfortunately very bad. And the progression-free survival in that population is probably more like 2 months. So this is a trial that has a very high likelihood of being positive because the possibility of long-term response is there, but even for patients who don't get a durable response, they're likely going to benefit more than they would have based on standard chemotherapy or retreatment with an anti–PD-1 agent. Dr. Diwakar Davar: Really, a very important trial to enroll, a trial that is first in many ways. First of a new generation of TCR-T agents, first trial to look at cell therapy in the control arm, a new standard of efficacy, but potentially also if this trial is successful, it will also be a new standard of trial conduct, a new kind of trial, of a set of trials that will be done in the second-line immunotherapy-refractory space. So let's pivot to the last trial that we were going to discuss, which was Abstract 2501. Abstract 2501 is a first-in-human phase 1/2 trial evaluating BNT142, which is the first-in-class mRNA-encoded bispecific targeting Claudin-6 and CD3 in patients with Claudin-positive tumors. We'll talk a little bit about this, but maybe let's start by talking a little bit about Claudin-6. So Claudin-6 is a very interesting new target. It's a target that's highly expressed in GI and ovarian tumors. There are a whole plethora of Claudin-6-targeting agents, including T-cell bispecifics and Claudin-6-directed CAR-Ts that are being developed. But BNT142 is novel. It's a novel lipid nanoparticle LNP-encapsulated mRNA. The mRNA encodes an anti–Claudin-6 CD3 bispecific termed RiboMAB-021. And it then is administered to the patient. The BNT142-encoding mRNA LNPs are taken up by the liver and translated into the active drug. So Jason, tell us a little bit about this agent. Why you think it's novel, if you think it's novel, and let's talk a little bit then about the results. Dr. Jason Luke: So I certainly think this is a novel agent, and I think this is just the first of what will probably become a new paradigm in oncology drug development. And so you alluded to this, but just to rehash it quickly, the drug is encoded as genetic information that's placed in the lipid nanoparticle and then is infused into the patient. And after the lipid nanoparticles are taken up by the liver, which is the most common place that LNPs are usually taken up, that genetic material in the mRNA starts to be translated into the actual protein, and that protein is the drug. So this is in vivo generation, so the patient is making their own drug inside their body. I think it's a really, really interesting approach. So for any drug that could be encoded as a genetic sequence, and in this case, it's a bispecific, as you mentioned, CD3-Claudin-6 engager, this could have a tremendous impact on how we think about pharmacology and novel drug development moving into the future in oncology. So I think it's an extremely interesting drug, the like of which we'll probably see only more moving forward. Dr. Diwakar Davar: Let's maybe briefly talk about the results. You know, the patient population was heavily pretreated, 65 or so patients, mostly ovarian cancer. Two-thirds of the patients were ovarian cancer, the rest were germ cell and lung cancer patients. But let's talk a little bit about the efficacy. The disease control rate was about 58% in the phase 1 population as a whole, but 75% in the ovarian patient population. Now tell us a little bit about the interesting things about the drug in terms of the pharmacokinetics, and also then maybe we can pivot to the clinical activity by dose level. Dr. Jason Luke: Well, so they did present in their presentation at ASCO a proportionality showing that as higher doses were administered, that greater amounts of the drug were being made inside the patient. And so that's an interesting observation, and it's an important one, right? Suggesting that the pharmacology that we classically think of by administering drugs by IV, for example, would still be in play. And that did translate into some level of efficacy, particularly at the higher dose levels. Now, the caveat that I'll make a note of is that disease control rate is an endpoint that I think we have to be careful about because what that really means is sometimes a little bit unclear. Sometimes patients have slowly growing tumors and so on and so forth. And the clinical relevance of disease control, if it doesn't last at least 6 months, I think is probably pretty questionable. So I think these are extremely interesting data, and there's some preliminary sense that getting the dose up is going to matter because the treatment responses were mostly observed at the highest dose levels. There's also a caveat, however, that across the field of CD3 bispecific molecules like this, there's been quite a bit of heterogeneity in terms of the response rate, with some of them only really generating stable disease responses and other ones having more robust responses. And so I think this is a really interesting initial foray into this space. My best understanding is this molecule is not moving forward further after this, but I think that this really does set it up to be able to chase after multiple different drug targets on a CD3 bispecific backbone, both in ovarian cancer, but then basically across all of oncology. Dr. Diwakar Davar: Perfect. This is a very new sort of exciting arena where we're going to be looking at, in many ways, these programmable constructs, whether we're looking at in vivo-generated, in this case, a T-cell bispecific, but we've also got newer drugs where we are essentially giving drugs where people are generating in vivo CAR T, and also potentially even in vivo TCR-T. But certainly lots of new excitement around this entire class of drugs. And so, what we'd like to do at this point in time is switch to essentially the fact that we've got a very, very exciting set of data at ASCO 2025. You've heard from Dr. Luke regarding the advances in both early drug development but also in advanced cutaneous melanoma. And Jason, as always, thank you so much for sharing your very valuable and great, fantastic insights with us on the ASCO Daily News Podcast. Dr. Jason Luke: Well, thanks again for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for taking your time to listen today. You will find the links to the abstracts that we discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:    Dr. Diwakar Davar    @diwakardavar    Dr. Jason Luke @jasonlukemd Follow ASCO on social media:     @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn   Disclosures:     Dr. Diwakar Davar:      Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences     Consulting or Advisory Role: Instil Bio, Vedanta Biosciences     Consulting or Advisory Role (Immediate family member): Shionogi     Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences     Research Funding (Inst.): Zucero Therapeutics     Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy     Dr. Jason Luke:     Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX     Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine     Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure     Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)     Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

Send us a textIn this episode of Clot Conversations, Dr. Lana Castellucci, University of Ottawa, discusses the COBRA study, which compares the bleeding risks of rivaroxaban and apixaban in patients with acute VTE. The study follows patients for three months and finds that apixaban significantly reduces combined bleeding events compared to rivaroxaban. While the trial wasn't powered for individual outcomes, it shows no difference in VTE recurrence. This is potentially practice-changing information, indicating that most acute VTE patients might benefit from apixaban over rivaroxaban, although patient-specific factors and preferences will still play a role in decision-making.Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

How can we avoid missing these rare but commonly missed injuries?   Check out the papers mentioned. Pelrine E, Larson E, Freilich A, Dacus AR, Deal N. Treatment and Outcomes of Missed Perilunate Dislocations: A Case Series. J Wrist Surg. 2023 May 8;13(2):171-175. doi: 10.1055/s-0043-1768929. PMID: 38505207; PMCID: PMC10948235. Link   Christina Nypaver, Stephen Liu. Perilunate injuries/lunate dislocations and radiocarpal dislocations.  Annals of Joint, Vol 6, Oct 15, 2021.  Link   Pinto A, Berritto D, Russo A, Riccitiello F, Caruso M, Belfiore MP, Papapietro VR, Carotti M, Pinto F, Giovagnoni A, Romano L, Grassi R. Traumatic fractures in adults: missed diagnosis on plain radiographs in the Emergency Department. Acta Biomed. 2018 Jan 19;89(1-S):111-123. doi: 10.23750/abm.v89i1-S.7015. PMID: 29350641; PMCID: PMC6179080. Link   Dixon A, Hacking C, Elfeky M, et al. Lunate dislocation. Reference article, Radiopaedia.org (Accessed on 26 Jun 2025) https://doi.org/10.53347/rID-10010    Dixon A, Hacking C, Sriselvakumar S, et al. Perilunate dislocation. Reference article, Radiopaedia.org (Accessed on 25 Jun 2025) https://doi.org/10.53347/rID-10004   www.rnzcuc.org.nz podcast@rnzcuc.org.nz https://www.facebook.com/rnzcuc https://twitter.com/rnzcuc   Music licensed from www.premiumbeat.com Full Grip by Score Squad   This podcast is intended to assist in ongoing medical education and peer discussion for qualified health professionals.  Please ensure you work within your scope of practice at all times.  For personal medical advice always consult your usual doctor 

There aren't many practitioners writing about today's topic. Unless, that is, you look up the collected works of Dr. Bill Dodson. Dr. Dodson is an award-winning board-certified psychiatrist and specialist in adult ADHD and his contributions to the study of Rejection Sensitive Dysphoria bring him to the show today. According to Dr. Dodson, nearly all those living with ADHD live with some level of rejection sensitivity, and thanks to the poor training on the ADHD connections to the condition, patients are going misdiagnosed and mistreated as a result.Today on the show, Dr. Dodson joins Nikki Kinzer and Pete Wright to discuss Rejection Sensitive Dysphoria and provide new language to frame a state those living with ADHD know all too well.About Dr. William DodsonDr. Bill Dodson is a award-winning board-certified psychiatrist and specialist in adult ADHD. While Dr. Dodson has been on the faculties of Georgetown University and the University of Colorado Health Sciences Center he is primarily a clinical practitioner who tries to combine evidence-based practice techniques with practice-based evidence.  In addition to being named a Life Fellow of the American Psychiatric Association, and recipient of the national Maxwell J. Schleifer Award for Distinguished Service to Persons with Disabilities, Dr. Dodson is one of two experts from the US to the World Anti-Doping program for the development of guidelines for the use of ADHD stimulant medications in the world's athletes.Links & NotesDr. William Dodson at Additudemag.com (00:00) - Welcome to The ADHD Podcast (02:24) - Become a Member of The ADHD Community (04:28) - Introducing Dr. William Dodson (05:53) - What is Rejection Sensitive Dysphoria? (10:59) - Defining Characteristics of RSD? (13:37) - Mental health trends (17:23) - RSD and Imposter Syndrome (20:15) - RSD and Gender (25:45) - Treatment paths for RSD (34:14) - RSD and ADHD Coaching (43:44) - Finding Dr. Dodson ★ Support this podcast on Patreon ★

Betsy Helmuth discusses premium membership perks, shares a squirrel eradication update, and celebrates a hot tub installation. She answers listener questions about displaying framed photos, mixing different types of art, and kitchen updates. Plus, there's a commercial break and an online class bundle promotion. 0:00 Premium membership benefits 1:32 Squirrel eradication update 3:29 Hot tub celebration 4:23 Design question submission 4:58 Kelsey's question on framed photos 6:55 Mixing different types of art 9:23 Placement of artwork 12:00 Online class bundle promotion 13:29 Rebecca's question on kitchen updates - Consider mixing different types and shapes of artwork to avoid making your space feel like a museum exhibit.  - When planning art placement, focus on where you want to draw attention and avoid overcrowding walls with too many pieces.  - In spaces with radiators, opt for blinds or Roman blinds over floor-length drapes to maintain functionality and aesthetics. Additional show notes: Click here to ask Betsy Helmuth a design question. Click here to upgrade to a premium member and access the bonus episodes. Click here to become an interior designer with Uploft's Interior Design Academy. For more affordable tips, visit AffordableInteriorDesign.com. For more about our residential interior design services, visit ModernInteriorDesign.com. For our commercial interior design services, visit OfficeInteriorDesign.com.

In this deeply compassionate episode of Motherhood Intended, Jacqueline opens up about the emotional toll of the “waiting season” during the fertility journey. Whether you're waiting for test results, a cycle to begin, or answers that feel impossibly out of reach, Jacqueline shares her own experiences and insights to help you feel seen and supported during this often invisible and very isolating stage. She offers grounding practices, mindset shifts, and an invitation to rest rather than constantly prepare — reminding you that this season is not wasted.What you'll hear:Why the “waiting season” can feel so overwhelming — and why it's not actually a passive phasePractical tools to ground yourself when everything feels out of control (daily rituals, journaling prompts, affirmations)The importance of reframing rest as necessary, not indulgent, while trying to conceiveHow therapy and community support can be essential tools, even if you're “just” in the waitingMentioned in the EpisodeClick here to take the Fertility Path QuizPLAYLISTS:TTC + InfertilityMiscarriage, Loss, & GriefWhen You or Your Child Are Given a DiagnosisPregnancy + PostpartumSurrogacyParenting + Self ImprovementTop 10 Episodes of 2024Connect with the podcast:Facebook: Motherhood Intended CommunityInstagram: @motherhood_intendedLeave a review for the podcastApply to be a guest on the show!Send us a Text Message with questions, suggestions, or to just say hello!Support the showIf you're interested in helping give the absolute greatest gift to deserving intended parents, learn more about becoming a surrogate (and earn up to $650 just for taking the first few simple steps!): share.conceiveabilities.com/hello12

*I caught this while editing, but want to acknowledge around 9:28 when I said "women fought to work" that women have always worked, especially women from disenfranchised socioeconomic backgrounds. what I meant by that statement was more around access to education, upward mobility in the workforce, equitable opportunities etc.**Please consider buying us a coffee or subscribing to a membership to help keep Centennial World's weekly podcasts going! Every single dollar goes back into this business

In the wellness world, many chase surface-level fixes, like creams, cleanses, and crash diets, while ignoring the internal systems that actually drive energy, detoxification, and glow. Cathy Goldstein, a holistic practitioner with over 40 years of experience, sees the body differently. She believes the real fix lies in supporting two overlooked systems: fascia and lymph. Cathy describes most people as walking around with a “traffic jam of toxins.” This buildup in the fascia and lymphatic system can lead to puffiness, swelling, fatigue, dull skin, and even emotional heaviness. Fascia is more than connective tissue—it's a collagen-producing communication network that sends energetic and structural signals faster than the nervous system. The lymphatic system flows through it, clearing toxins and nourishing cells. Trauma, pollution, poor posture, or emotional baggage can block this flow. When that happens, not only does your body hold onto physical toxins, but emotional ones too. Fascia, Emotions & Self-Healing Cathy often says, “The issues are in the tissues.” She connects stuck emotions and trauma to disruptions in the fascia. By using energetic tools and neuro-emotional techniques, she helps the body rewire these patterns and release stored pain—both physical and emotional. Her approach is about restoration, not force. Treatments aim to retrain the nervous system, restore vibrational balance, and activate the body's own self-healing mechanisms. A New Kind of Skincare Instead of applying collagen to the skin, Cathy developed a skincare line that teaches your cells to regenerate it. Her frequency-imprinted body lotion uses oleosome technology to deliver nutrients deep into the skin. Each green bead inside contains thousands of energetic signatures and bioadaptive ingredients that encourage skin to rebuild from the inside out. This is skincare that talks to your cells—helping them remember how to function at their best. Body Sculpting with Purpose Forget bruising Gua Sha tools. Cathy's True Energy Body Sculpting Stone is ergonomically designed and infused with healing frequencies. Used just 5–6 minutes daily—especially after a shower or sauna—it opens lymphatic channels, clears fascia adhesions, and sculpts areas like thighs, belly, and underarms. Users report visible results in days: Crêpy skin softens Skin lifts and plumps in under 2 weeks Energy and emotional clarity improve It even stimulates the brain's glymphatic system to support detox while you sleep. In this podcast you'll learn... Why fascia and lymph are the missing pieces in your wellness puzzle How emotional trauma gets stored in your tissues Why fascia moves energy faster than your nervous system How Cathy's skincare and body tools promote deep healing and visible transformation Daily rituals that take just 6 minutes but create lasting impact Why aging doesn't have to mean decline—it can be intuitive, vibrant, and empowered EPISODE RESOURCES: Website Social Media handles: Facebook Instragram TikTok Youtube        

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

Seizures, sleepless nights, and mysterious white patches on his skin marked the beginning of Daniel's journey with Tuberous Sclerosis Complex (TSC). Diagnosed at age 6, Daniel faced a childhood filled with MRIs, EEGs, and specialist visits, often requiring cross-country travel for coordinated care. In this moving episode of On Rare, David Rintell, Head of Patient Advocacy at BridgeBio, and Mandy Rohrig, Senior Director of Patient Advocacy at BridgeBio Gene Therapy, speak with Daniel, a 31-year-old living in Seattle, about growing up with TSC, the emotional toll of visible symptoms, and the stigma he faced from peers. He reflects on the cognitive and mood impacts of TSC, including OCD and outbursts, and how he often kept to himself to feel more accepted. Today, Daniel is an active advocate in the TSC community, emphasizing the importance of connection, representation, and finding support among those with shared experiences. As he puts it, “You have to find your people.” Che-Wei Chang, Principal Scientist at BridgeBio, presents a medical overview of Tuberous Sclerosis Complex (TSC), a rare genetic disorder marked by seizures and benign tumors throughout the body. TSC results from a spontaneous mutation in a single copy of the TSC1 or TSC2 gene, which normally inhibit mTOR, an enzyme that regulates cell growth. Loss of this inhibition leads to mTOR hyperactivation, leading to abnormal cell proliferation and tumors in the brain, kidneys, skin, and other organs. Diagnosis typically involves identifying tubers in the brain along with tumors in other organs and is confirmed through genetic testing. Treatments include mTOR inhibitors, which are effective against many TSC-related tumors, and anti-seizure medications, although drug resistance is common.

UCSF's Dr. Rahul Aggarwal explains the role of clinical trials in advancing prostate cancer treatment and how trial design is evolving to match today's more personalized approaches. He highlights how UCSF has contributed to major prostate cancer therapies and emphasizes the importance of genetic and genomic testing in identifying suitable trials for each patient. Dr. Aggarwal explains the different trial phases, clarifies common myths—such as concerns about placebos—and stresses that trials are considered at every stage of disease. He also discusses efforts to improve access, affordability, and diversity in trial participation, including regional partnerships and digital matching tools. The talk encourages patients to be informed and proactive when considering clinical trials as part of their treatment plan. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40800]

When you think about someone taking a psychedelic drug like magic mushrooms, the first images that come to mind probably don't involve a medical professional in a white coat or any sort of clinical setting. However, the perception of these drugs is changing as researchers and health professionals continue to learn new ways these drugs can treat a variety of mental health conditions. Much of the research has to do with microdosing, or taking such a small dose of a drug that it doesn't produce a “trip.” One of the more commonly microdosed drugs is psilocybin, the naturally occurring psychedelic compound found in “magic mushrooms.” That led our small-but-mighty team at Hyperfocus to wonder, “What could this all mean for ADHD treatment?” So, we looked for someone who might know, and it led us to Dr. Richard A. Friedman. He's a professor, psychiatrist, and director of the Psychopharmacology Clinic at Weill Cornell Medicine, Cornell University's medical school. Richard has also written about his areas of expertise for The New York Times and is a contributing writer at The Atlantic.  On this week's episode of Hyperfocus, he sits down with mental health journalist Rae Jacobson to answer all her questions on microdosing, psychedelics as medicine, and what it could mean for ADHD and more. Related resourcesADHD alternative treatmentADHD treatment without medication: What are my options?Richard's piece on microdosing in The AtlanticTimestamps(02:58) What is microdosing?(10:43) What do we know about ADHD and microdosing?(15:30) How do psychedelics work in the brain?(30:44) Richard's hopes for future research and microdosingFor a transcript of this episode and more resources, visit the episode page on Understood.org.We love hearing from our listeners! Email us at hyperfocus@understood.org. Understood.org is a nonprofit organization dedicated to empowering people with learning and thinking differences, like ADHD and dyslexia. If you want to help us continue this work, donate at understood.org/give

Please visit answersincme.com/ABT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses the clinical evidence for novel complement (C5) inhibitors in the treatment of generalized myasthenia gravis (gMG) and personalized multidisciplinary management strategies. Upon completion of this activity, participants should be better able to: Review the rationale for novel C5 inhibitors in the treatment of generalized myasthenia gravis (gMG); Describe the long-term clinical data of C5 inhibitors for the treatment of gMG; and Discuss strategies to personalize multidisciplinary management plans for patients with gMG.

Join Professor Iain McInnes and Professor Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss three papers: the impact of TOF treatment on weight and BMI in RA patients, to that of alternate treatment options for RA patients with prior MTX-inadequate response, and the treatment of JAKis versus TNFis in RA.

The so-called post-code lottery is back in the spotlight the issue of where someone lives being the major factor in getting surgery, instead of how sick they are. College of Surgeons chairperson Ros Pochin spoke to Ingrid Hipkiss.

Interview with Kristopher Paolino, MD.

UCSF's Dr. Rahul Aggarwal explains the role of clinical trials in advancing prostate cancer treatment and how trial design is evolving to match today's more personalized approaches. He highlights how UCSF has contributed to major prostate cancer therapies and emphasizes the importance of genetic and genomic testing in identifying suitable trials for each patient. Dr. Aggarwal explains the different trial phases, clarifies common myths—such as concerns about placebos—and stresses that trials are considered at every stage of disease. He also discusses efforts to improve access, affordability, and diversity in trial participation, including regional partnerships and digital matching tools. The talk encourages patients to be informed and proactive when considering clinical trials as part of their treatment plan. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40800]

UCSF's Dr. Rahul Aggarwal explains the role of clinical trials in advancing prostate cancer treatment and how trial design is evolving to match today's more personalized approaches. He highlights how UCSF has contributed to major prostate cancer therapies and emphasizes the importance of genetic and genomic testing in identifying suitable trials for each patient. Dr. Aggarwal explains the different trial phases, clarifies common myths—such as concerns about placebos—and stresses that trials are considered at every stage of disease. He also discusses efforts to improve access, affordability, and diversity in trial participation, including regional partnerships and digital matching tools. The talk encourages patients to be informed and proactive when considering clinical trials as part of their treatment plan. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40800]

UCSF's Dr. Rahul Aggarwal explains the role of clinical trials in advancing prostate cancer treatment and how trial design is evolving to match today's more personalized approaches. He highlights how UCSF has contributed to major prostate cancer therapies and emphasizes the importance of genetic and genomic testing in identifying suitable trials for each patient. Dr. Aggarwal explains the different trial phases, clarifies common myths—such as concerns about placebos—and stresses that trials are considered at every stage of disease. He also discusses efforts to improve access, affordability, and diversity in trial participation, including regional partnerships and digital matching tools. The talk encourages patients to be informed and proactive when considering clinical trials as part of their treatment plan. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40800]

Last month, scientists reported a historic first: they gave the first personalized gene-editing treatment to a baby who was born with a rare life-threatening genetic disorder. Before the treatment, his prognosis was grim. But after three doses, the baby's health improved. So how does it work? What are the risks? And what could this breakthrough mean for the 30 million people in the US who have a rare genetic disease with no available treatments?To help get some answers, Host Flora Lichtman is joined by the physician-scientists who led this research: geneticist Dr. Kiran Musunuru and pediatrician Dr. Rebecca Ahrens-Nicklas.Guests: Dr. Rebecca Ahrens-Nicklas is an assistant professor of pediatrics and genetics at the Children's Hospital of Philadelphia and the University of Pennsylvania.Dr. Kiran Musunuru is a professor of translational research at the University of Pennsylvania.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Are you truly allergic to dairy or just intolerant? Can headaches, joint pain or fatigue be signs of hidden allergies? And what about those online food intolerance tests? Can you trust them?In this episode, Dr Helen brings clarity and evidence to the confusing world of food allergies, intolerances and sensitivities.We cover:

Hypoglycemia can be subtle—or dangerously obvious—and knowing when and how to treat it is critical. In her first episode as our new Push Dose Pearls expert, Emergency Medicine Clinical Pharmacist, Haley Burhans, joins us to break it down. We discuss glucose thresholds by age, when to draw critical labs, and how to choose the right treatment—whether it's oral glucose, IV dextrose, or IM or intranasal glucagon. From neonates to older adults, Haley delivers practical, evidence-based pearls to help you manage low blood sugar safely and effectively in the ED. Was this episode helpful? What other medications would you like to learn more about? Hit us up on social media @empulsepodcast or at ucdavisem.com Hosts: Dr. Julia Magaña, Professor of Pediatric Emergency Medicine at UC Davis Dr. Sarah Medeiros, Professor of Emergency Medicine at UC Davis Guests: Haley Burhans, PharmD, Emergency Medicine Clinical Pharmacist at UC Davis Resources: Gandhi K. Approach to hypoglycemia in infants and children. Transl Pediatr. 2017 Oct;6(4):408-420. doi: 10.21037/tp.2017.10.05. PMID: 29184821; PMCID: PMC5682370. Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, Haller MJ, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW; T1D Exchange Intranasal Glucagon Investigators. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. Diabetes Care. 2016 Feb;39(2):264-70. doi: 10.2337/dc15-1498. Epub 2015 Dec 17. PMID: 26681725; PMCID: PMC4722945.. MD Calc GIR (Glucose Infusion Rate) Calculator **** Thank you to the UC Davis Department of Emergency Medicine for supporting this podcast and to Orlando Magaña at OM Productions for audio production services.

In this highly requested episode of Beauty Curious, Ian Michael Cru and board-certified dermatologist Dr. Elise Love take a deep dive into melasma—one of the most misunderstood and frustrating skin conditions.Learn what causes melasma, how it shows up on the face, and why some treatments work better than others. The duo unpacks the five major triggers—hormones, sunlight, heat, pollution, and irritants—and offers expert guidance on navigating both quick-action treatments like hydroquinone and long-term maintenance with topical routines.Plus, get insider tips on OTC solutions, when to seek professional care, and which in-office procedures (like lasers and peels) are worth considering—and which ones to approach with caution.What You'll Learn:What melasma is and how it typically appearsThe top 5 triggers that worsen melasmaHow hydroquinone fits into a smart treatment planSafe and effective advanced procedures for stubborn pigmentationExpert over-the-counter product picks to use while you wait to see a derm

Can addressing the body's metabolism really make a difference in cancer care? Henning Saupe, MD, author of Holistic Cancer Medicine, and founder of Arcadia Praxisklinik, believes it can, and must. After witnessing the toll conventional treatments took on his mother, Dr. Saupe was inspired to explore a gentler, more supportive path. He now helps patients […]

Lumbar discectomy is a surgical procedure designed to relieve pressure on spinal nerves caused by a herniated disk. Unlike traditional open surgery, this technique uses small incisions and specialized tools to remove damaged disk material with minimal impact on surrounding tissue. Patients typically experience less pain and quicker recovery, making it a preferred option when conservative treatments fail.

In this episode of Derms and Conditions, host James Q. Del Rosso, DO, is joined by a world expert in pigmentation, Seemal R. Desai, MD, founder of Innovative Dermatology in Dallas, Texas, for a timely, clinically focused discussion on vitiligo. Dr Desai begins by outlining how to identify unstable vitiligo at the first visit, a crucial step that guides treatment decisions. He describes hallmark features of instability, including trichrome lesions, confetti-like depigmentation, inflammatory borders, pruritus, and signs of Koebnerization—and emphasizes that even one unstable lesion should prompt systemic stabilization. Vitiligo flares can occur unpredictably, even in previously stable patients. The conversation also explores common comorbidities, including autoimmune thyroid disease, diabetes mellitus, and alopecia areata. Dr Desai shares his standard lab workup at the initial visit, which includes thyroid-stimulating hormone, free thyroxine, thyroid peroxidase antibody, and vitamin D. They discuss when to repeat testing and how to interpret elevated thyroid antibody titers in asymptomatic patients. The pair also touches on psychosocial impact, especially among children and adolescents, and strategies to create space for emotional check-ins during clinical visits. In the second half of the episode, Dr Desai shares practical insights on using topical ruxolitinib cream 1.5% for nonsegmental vitiligo. Dr Del Rosso and Dr Desai discuss treatment duration, counseling around delayed response, and why BID application is critical for success. They also address combining ruxolitinib with phototherapy, tailoring treatment based on location and follicular density, and how to support patients who may feel discouraged by early speckled repigmentation. Boxed warning concerns are also reviewed, with a focus on safety and real-world reassurance for patients using topical formulations. Dr Desai closes with an essential message: patients with vitiligo deserve more than a one-line treatment plan. Hope, education, and long-term partnership are key—and new therapeutic options are on the horizon.

Join hosts Shaiey Hoogendoorn and Dr. Andrea Vassilev in an enlightening discussion focusing on the often misunderstood concept of mixed features. With personal anecdotes and professional insights, they unpack what it means to experience mixed episodes and how these can present in daily life. This episode sheds light on diagnostic challenges, common misconceptions, and the importance of accurate treatment. Additionally, the episode touches on the risks associated with mixed features, including heightened impulsivity and agitation. Listen in as they explore how living through these experiences can feel like being on two roller coasters at once, and the vital need for advocacy and self-awareness in managing mood disorders. This episode is a testament to the power of shared knowledge and community healing. this is bipolar... (00:10:08) The Complexity of Diagnosis (00:12:28) Dr Andrea's upcomig workbook book on Self Stigma (00:16:43) Personal Experience with Mixed Features (00:21:35) Navigating Mixed Features (00:27:09) Agitation & Despair (00:30:52) Urgency of Treatment (0035:46) Encouragement & Resistance (00:39:32) Closing Thoughts & Community Call to Action Connect with us: IG @this.is.bipolar Youtube: this is bipolar channel TT @this.is.bipolar thisisbipolar.com   Thank you from the bottom of my heart for listening. If this episode or podcast means something to you, I would be forever grateful if you would follow/subscribe the ‘this is bipolar' podcast wherever you listen to your podcasts so you stay up to date. It would also mean the world to me if you gave a 5 ⭐️ star review- this helps the podcast reach those who need to hear it most.  Much love, Shaley xo  More about your Host: Shaley Hoogendoorn is a speaker, content creator and currently hosts the popular “this is bipolar” vlog and podcast. She lives with bipolar 2 disorder and shares her story and the stories of others to dismantle the stigma around mental illness.  Shaley is passionate about educating and empowering others about bipolar disorder. She has contributed to publications for Sanctuary Ministries, Psych Central and BP Hope magazine. She hosted a series interviewing women living with mental illnesses at SheLoves Magazine in a series named "Sisters in Mental Illness."  Shaley's greatest hope is that creating safe spaces to connect will give hope and comfort those that struggle. Meet our Guest Co-Host: Dr. Andrea Vassilev holds a doctorate in psychology, is a therapist in California, and has lived with bipolar disorder for over 25 years. Andrea is the creator of the program Overcoming Self-Stigma in Bipolar Disorder and serves on the Board of Directors of the International Society for Bipolar Disorders. As a clinician and academic with lived experience, Andrea brings a special perspective to both her professional and advocacy work. Andrea hopes that by telling her own story of life with bipolar disorder through the lenses of clinical causes, treatments, and outcomes that she can provide education, hope, and comfort to others. You can connect with her on Instagram @best.life.bipolar or at www.andreavassilev.com. IG @this.is.bipolar Youtube: this is bipolar channel TT @this.is.bipolar thisisbipolar.com Thank you from the bottom of my heart for listening. If this episode or podcast means something to you, I would be forever grateful if you would follow/subscribe the ‘this is bipolar' podcast wherever you listen to your podcasts so you stay up to date. It would also mean the world to me if you gave a 5 ⭐️ star review- this helps the podcast reach those who need to hear it most.  Much love, Shaley xo  More about your Host: Shaley Hoogendoorn is a speaker, content creator and currently hosts the popular “this is bipolar” vlog and podcast. She lives with bipolar 2 disorder and shares her story and the stories of others to dismantle the stigma around mental illness.  Shaley is passionate about educating and empowering others about bipolar disorder. She has contributed to publications for Sanctuary Ministries, Psych Central and BP Hope magazine. She hosted a series interviewing women living with mental illnesses at SheLoves Magazine in a series named "Sisters in Mental Illness."  Shaley's greatest hope is that creating safe spaces to connect will give hope and comfort those that struggle. Meet our Guest Co-Host: Dr. Andrea Vassilev holds a doctorate in psychology, is a therapist in California, and has lived with bipolar disorder for over 25 years. Andrea is the creator of the program Overcoming Self-Stigma in Bipolar Disorder and serves on the Board of Directors of the International Society for Bipolar Disorders. As a clinician and academic with lived experience, Andrea brings a special perspective to both her professional and advocacy work. Andrea hopes that by telling her own story of life with bipolar disorder through the lenses of clinical causes, treatments, and outcomes that she can provide education, hope, and comfort to others. You can connect with her on Instagram @best.life.bipolar or at www.andreavassilev.com.

To pass ACLS, you will need to be able to identify common rhythms on a monitor during your mega code and ECG strips on your written exam.If you don't normally monitor patients as part of your job, I suggest two things:1. Find a system for ECG interpretation that works well for you; and2. Practice reading ECGs every day for a few weeks before your class.Review of normal ECG morphology of P wave, QRS complex, and T wave in lead II.Characteristics of first degree heart block.Characteristics of third degree (complete) AV block.Treatment of unstable patients in third degree block following the ACLS Bradycardia algorithm. Special considerations for use of Atropine when patients are in a third degree heart block.The use of TCP, Dopamine, & Epinephrine drip for unstable bradycardic patients refractory to Atropine.Good luck with your ACLS class!Links: Buy Me a Coffee at https://buymeacoffee.com/paultaylor Practice ECG rhythms at Dialed Medics - https://dialedmedics.com/Free Prescription Discount Card - Download your free drug discount card to save money on prescription medications for you and your pets: https://safemeds.vipPass ACLS Web Site - Episode archives & other ACLS-related podcasts: https://passacls.com@Pass-ACLS-Podcast on LinkedIn

Send us a textIn this WTR Symposium Series podcast, " CATCH THE WAVE: Investing in Water Treatment and Solutions ", management of Arq, Inc. (ARQ), California Water Service (CWT), National Energy Services Reunited (NESR), and Select Water Solutions (WTTR) join the Water Tower Research team including Shawn Severson, CEO and Co-founder, Jeff Robertson, Managing Director – Natural Resources, and Peter Gastreich, Senior Energy and Sustainable Investing Analyst to discuss growth strategies. The participating companies are delivering key water treatment technologies, water management solutions, and long-term infrastructure services for customers in energy, utilities, specialty materials and other industries.  

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/CEH865. CME/AAPA credit will be available until July 3, 2026.Alzheimer's Disease Neuroradiology Case Conference: Mastering the New Frontier in Diagnosis and Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QPE865. CME/MOC/AAPA credit will be available until June 20, 2026.Advancing Care for Chronic Spontaneous Urticaria: Navigating an Evolving Treatment Landscape for Optimal Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Sanofi and Regeneron Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

Both the BC NDP and the Conservative Party of BC have pledged to expand involuntary care under the Mental Health Act for people who use drugs. More than 17 organizations have condemned forced detention plans, including the BC Civil Liberties Association and the Vancouver Area Network of Drug Users. Meenakshi Mannoe is connected to anti-prison and anti-policing movements and has previously engaged in advocacy related to the expansion of involuntary care. We speak with her about this issue.

Crushing it professionally, but feeling empty inside? This is what Dr. Judith Joseph calls, “high-functioning depression.” Here's what's really happening: You're pathologically productive, wearing a mask of success while experiencing anhedonia — the clinical term for losing joy in things that once lit you up. In this episode, she breaks down the five V's framework that can restore your natural capacity for joy. What's one small thing you're going to plan joy into your week? Ready to take back control of your cellular biology? Join my FREE 3-Day Ultimate Detox Challenge starting June 23rd. I've taken the exact protocols I use with pro athletes and CEOs and simplified them for everyday implementation. Sign up here: https://bit.ly/3ZgCW4u Join the Ultimate Human VIP community: https://bit.ly/4ai0Xwg Connect with Dr. Judith Joseph: Get Dr. Judith Joseph's book, “High Functioning“ here: https://bit.ly/4kn8Bct  Listen to "The Vault with Dr. Judith" on all your favorite platforms! YouTube: https://bit.ly/4lhTsd5  Spotify: https://bit.ly/4lqfURz  Apple Podcasts: https://bit.ly/3ZFoUd6    Connect with Dr. Judith Joseph: Website: https://bit.ly/4kTr411  YouTube: https://bit.ly/4l5AC9e  Instagram: https://bit.ly/4kXdiux  TikTok: https://bit.ly/44tPvwg Facebook: ⁠https://bit.ly/3G8QDMC LinkedIn: https://bit.ly/4egyTLH  Thank you to our partners: H2TABS - USE CODE “ULTIMATE10” FOR 10% OFF: https://bit.ly/4hMNdgg BODYHEALTH - USE CODE “ULTIMATE20” FOR 20% OFF: http://bit.ly/4e5IjsV BAJA GOLD - USE CODE "ULTIMATE10" FOR 10% OFF: https://bit.ly/3WSBqUa EIGHT SLEEP - SAVE $350 ON THE POD 4 ULTRA WITH CODE “GARY”: https://bit.ly/3WkLd6E COLD LIFE - THE ULTIMATE HUMAN PLUNGE: https://bit.ly/4eULUKp WHOOP - GET 1 FREE MONTH WHEN YOU JOIN!: https://bit.ly/3VQ0nzW MASA CHIPS - GET 20% OFF YOUR FIRST ORDER: https://bit.ly/40LVY4y VANDY - USE CODE “ULTIMATE20” FOR 20% OFF: https://bit.ly/49Qr7WE AION - USE CODE “ULTIMATE10” FOR 10% OFF: https://bit.ly/4h6KHAD HAPBEE - FEEL BETTER & PERFORM AT YOUR BEST: https://bit.ly/4a6glfo CARAWAY - USE CODE “ULTIMATE” FOR 10% OFF: https://bit.ly/3Q1VmkC HEALF - GET 10% OFF YOUR ORDER: https://bit.ly/41HJg6S BIOPTIMIZERS - USE CODE “ULTIMATE” FOR 10% OFF: https://bit.ly/4inFfd7 RHO NUTRITION - USE CODE “ULTIMATE15” FOR 15% OFF: https://bit.ly/44fFza0 GENETIC TEST: ⁠https://bit.ly/3Yg1Uk9 Watch  the “Ultimate Human Podcast” every Tuesday & Thursday at 9AM EST: YouTube: https://bit.ly/3RPQYX8 Podcasts: https://bit.ly/3RQftU0 Connect with Gary Brecka: Instagram: https://bit.ly/3RPpnFs TikTok: https://bit.ly/4coJ8fo X.com: https://bit.ly/3Opc8tf Facebook: https://bit.ly/464VA1H LinkedIn: https://bit.ly/4hH7Ri2 Website: https://bit.ly/4eLDbdU Merch: https://bit.ly/4aBpOM1 Newsletter: https://bit.ly/47ejrws Ask Gary: https://bit.ly/3PEAJuG Timestamps: 00:00 Intro 02:20 Dr. Judith Joseph's Research on Anhedonia and Joy 08:21 Understanding the Science of Happiness 15:01 Testing for Mental Health 20:37 High-Functioning Depression Definition 22:54 Identifying and Processing Trauma 30:28 The Five V's 45:17 Creating Social Connections 58:57 Shifting the Mindset on Self-Care 1:02:00 Planning Joy 1:09:50 Impact of Physical Movement on Mental Health 1:13:46 Final Question: What does it mean to you to be an “Ultimate Human?” The Ultimate Human with Gary Brecka Podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The Content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions. Learn more about your ad choices. Visit megaphone.fm/adchoices

Today I'm joined by wrestler, jiu-jitsuka, and author Chris Jessulat (https://www.thewrongsideof35.com/) to discuss the best practices for staying relevant on the mats as you enter your fourth decade and beyond... 00:00 Training as an Older Grappler 02:48 The Transition from Competitive to Recreational Training 05:46 Physical Changes and Changing to a Mobility Focus 08:34 Quantifying Progress in Jiu-Jitsu 11:47 Breaking Through Training Plateaus 14:23 Comfort in Unfamiliar Positions 17:11 Training Strategies for Older Grapplers 29:35 Creating Positive Training Environments 31:12 The Impact of Focussing on Recovery and Positive Lifestyle Choices 33:41 Proactive Injury Management and Recovery Strategies 37:44 Navigating Injury Diagnosis and Treatment 40:51 Adapting Techniques and Mindset in Training 44:22 Reflections on Writing and Sharing Martial Arts Experiences 48:26 Lessons Learned from Martial Arts Training 51:20 The Importance of Community in Martial Arts If you've read this far down then check out my best-selling book Perseverance, Life and Death in the Subarctic, available everywhere including Amazon: https://www.amazon.com/Perseverance-Death-Subarctic-Stephan-Kesting/dp/1639368612/

In this episode, Kirsten discusses her passion for soft wax and addresses common misconceptions in the waxing industry. Kirsten also explores the realities of business ownership in the aesthetics field and encourages ongoing education for professionals. The conversation aims to inspire and educate listeners about the waxing process and the beauty industry.More on Enso:⁠⁠https://ensowax.com/⁠⁠⁠⁠https://www.instagram.com/ensowax/⁠⁠Follow me on Instagram

In this groundbreaking episode of Sober is Dope, we sit down with Dr. David Clarke, President of the Association for the Treatment of Neuroplastic Symptoms (ATNS), to uncover how unresolved trauma and deep stress can literally rewire the brain to create chronic pain, illness, and suffering.Dr. Clarke shares how Neuroplastic Recovery Therapy (NRT) is helping thousands find relief — outperforming Cognitive Behavioral Therapy (CBT) in clinical studies — and offers hope for people in recovery who are still battling invisible illnesses like fibromyalgia, migraines, IBS, and more.If you or someone you love is sober, but still suffering from chronic pain or fatigue with no clear diagnosis, this episode is a must-listen.⸻

Counseling patients with intermediate-risk non-muscle invasive bladder cancer can be complex, with a wide range of treatment options and care pathways. In this episode of BackTable Urology, urologic oncologists Dr. Ruchika Talwar and Dr. Kelly Bree explore how to approach this challenge with clarity and compassion. --- This podcast is supported by an educational grant from UroGen Pharma. --- SYNPOSIS They emphasize a shift toward patient-centered, less aggressive treatment strategies, highlighting the importance of quality of life in clinical decision-making. The discussion includes risk stratification, the use of intravesical gemcitabine, and ongoing clinical trials. Dr. Bree also offers actionable tips for optimizing patient preparation and recovery. This episode underscores the growing importance of listening to patient voices to shape future standards of care. --- TIMESTAMPS 00:00 - Introduction and Overview02:09 - Risk Stratification and Treatment Approaches06:12 - Intravesical Therapy Options08:47 - Quality of Life and Patient Counseling12:56 - Practical Tips for TURBT Recovery17:03 - In-Office Procedures and Patient Management21:23 - Resources and Support for Patients24:13 - Future Directions and Final Thoughts --- RESOURCES Society of Urologic Oncologyhttps://suonet.org/home.aspx

Sinusitis or migraine? Understanding the difference between rhinogenic and primary headaches could change your treatment algorithm. In this episode of Backtable ENT, Dr. Jessica Lee, an otolaryngologist from Charleston ENT and Allergy, discusses the prevalence and treatment of sinus headaches with hosts Dr. Gopi Shah and Dr. Ashley Agan. --- SYNPOSIS The doctors discuss how half of sinus infection diagnoses are often misdiagnosed, with many patients having normal CT scans and nasal endoscopies. Dr. Lee emphasizes the importance of distinguishing between sinus-related headaches and migraines, noting that 80% of sinus headache complaints meet migraine criteria. The conversation covers the use of lifestyle medicine, supplements, medications, and the role of neurologists in managing chronic headaches. Dr. Lee also touches on the role of mycotoxins, drawing from evidence-based practices while stressing patient education and collaboration in treatment. --- TIMESTAMPS 00:00 - Introduction 04:10 - Differentiating Sinus Headaches from Other Conditions10:07 - Lifestyle Factors and Migraine Management25:45 - Supplements and Treatments for Migraine30:01 - Iron Supplementation and Dietary Adjustments31:42 - Medication Management for Migraines34:52 - Botox as a Treatment Option44:50 - Mycotoxins and Mold Illness50:11 - Non-Pharmacologic Options for Headaches54:00 - Final Thoughts and Recommendations --- RESOURCES Dr. Jessica Leehttps://charlestonent.com/bio/jessica-lee/

Episode Overview:In this episode, host Cali Werner welcomes special guest Jelani Daniel, a seasoned clinician specializing in anxiety and related disorders. Together, they explore the complexities of hoarding disorder, its psychological impacts, and the importance of compassion and understanding in supporting those affected. They discuss common misconceptions about hoarding, the distinctions between hoarding and collecting, and share valuable resources for both individuals struggling with hoarding and their loved ones.Key Insights:What is Hoarding Disorder? Defined by persistent difficulty in discarding possessions, regardless of their value, which can severely impact living spaces.Misconceptions: The portrayal of hoarders in media, especially reality TV, often emphasizes extreme cases and does not represent the average experience.Hoarding vs. Collecting: Important distinctions exist; collectors are organized and display items, whereas hoarding presents a cluttered living environment without utility.Support for Family Members: Encouragement for family and friends to seek their own support while navigating the challenges of living with or supporting someone who hoards.Notable Quotes:"Hoarding can look a lot of different ways." – Cali Werner"Cleanouts do not treat the individual; they treat the house." – Jelani Daniel"Not all clutter is hoarding, and not all clutter is due to hoarding disorder." – Jelani DanielTimestamps:[00:00:00] - Introduction to the episode and hosts[00:01:10] - Introduction of guest Jelani Daniel[00:05:00] - Discussion on what defines hoarding disorder[00:10:09] - Impact of hoarding on individuals and families[00:16:45] - Misconceptions about hoarding vs. collecting[00:24:38] - Understanding the psychological aspects of treatment[00:39:40] - Resources for family members and support groups[00:43:01] - Conclusion and call to actionRelevant Resources:Houston OCD Support: houstonocdsupport.orgFamily as Motivators: gregchasson.comNational Alliance on Mental Illness (NAMI): nami.orgCall to Action:If you found insights in this episode beneficial, please subscribe to our podcast on your favorite platform, leave us a review, and share your thoughts or questions on social media! Connect with us on Instagram @theanxietysocietypod or visit our website at anxietysocietypodcast.com to engage with our growing community.

In this episode of PT Snacks Podcast, host Kasey Hankins addresses the challenge of identifying and treating bone stress injuries (BSIs) before they progress into stress fractures. Kasey delves into the biology of bone stress, detailing how osteoblasts and osteoclasts respond to stress, and discusses common risk factors for BSIs among athletes and military personnel. The episode offers practical advice on clinical assessment, including the limitations of x-rays and the benefits of MRIs, and provides strategies for effective treatment and prevention through offloading, load restoration, and performance enhancement phases. Listeners are encouraged to watch out for early symptoms and are directed to additional resources for continuing education.00:00 Introduction to Bone Stress Injuries01:15 Understanding Bone Stress Injuries (BSIs)04:18 Risk Factors and Clinical Presentation07:20 Diagnosis and Imaging Techniques09:15 Treatment and Rehabilitation Phases13:03 Summary and Additional ResourcesGet $126 off an individual MedBridge subscription or 10% off a group plan during their Mid-Year Anniversary Sale, June 23–30! Use code PTSNACKSPODCASTSUMMER at checkout.

Join us as we review recent practice-changing articles on the effect of combination statin and ezetimibe in reducing myalgias, male partner treatment for BV, semaglutide for MASH/liver fibrosis, exercise and cancer risk, and cytisinicline for smoking cessation. Fill your brain hole with some delicious apps and entrees from our spring Digests! Featuring Paul Williams (@PaulNWilliamz), Nora Taranto (@norataranto), special guest epidemiologist Alexander Chaitoff (@alexchaitoff) and Matt Watto (@doctorwatto). Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Credits Written and Hosted by: Nora Taranto MD; Alexander Chaitoff MD, MPH; Paul Williams, MD, FACP, Matthew Watto MD, FACP, Alex Chaitoff MD MPH  Cover Art: Nora Taranto MD Reviewer: Leah Witt MD  Technical Production: Pod Paste Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Show Segments Intro, disclaimer Self-collected HPV tests for cervical cancer screening  Semaglutide for MASH/Liver Fibrosis Male Partner Treatment for BV  Statins plus ezetimibe versus high-dose statins alone for statin-associated muscle symptoms  Exercise and Colon Cancer Risk  Cytisinicline for Smoking Cessation  Outro Sponsor: FIGS Curbsiders listeners can get 15% off. Just go to wearFIGS.com and use code FIGSRX Sponsor: Quince Go to Quince.com/curb for free shipping on your order and 365 day returns.  Sponsor: Continuing Education Company Curbsiders listeners get 45% off select online courses with promo code Curb45, through July 30. You can also use Curb30 for 30% off all webcasts and on demand replay courses. Check it all out at CMEmeeting.org/curbsiders.

In this episode, Dr. Anthony Youn, "America's holistic plastic surgeon," answers Instagram followers' questions in an "Ask Me Anything" format. He discusses topics like plastic surgery advice, skincare, under-eye bags, AI in endorsements, patient stories, and cosmetic treatments. Dr. Youn shares personal experiences—including a dramatic patient encounter—offers professional insights, and emphasizes patient safety and informed decision-making. He also highlights the importance of healthy habits and invites listeners to support the show with ratings or reviews. The episode blends practical advice with engaging anecdotes from his career. Links and Resources: Where can you find more information about how to autojuvenate your skin to a younger you? Check out my new book, Younger For Life! It's available at ⁠⁠⁠⁠⁠⁠https://autojuvenation.com⁠⁠⁠⁠⁠⁠, and if you buy it now, you will receive over $100 in FREE gifts, including a $30 gift certificate for my online store ⁠⁠⁠⁠⁠⁠younbeauty.com⁠⁠⁠⁠⁠⁠! Check out Dr. Youn's skincare products and nutritional supplements - ⁠⁠⁠⁠⁠⁠younbeauty.com⁠⁠⁠⁠⁠⁠ Download his FREE eGuide: "What to Eat to Look Younger" - ⁠⁠⁠⁠⁠⁠dryoun.com/eat-look-younger⁠⁠⁠⁠⁠⁠ Follow Dr. Youn on Instagram - ⁠⁠⁠⁠⁠⁠@tonyyounmd⁠⁠⁠⁠⁠⁠ Follow Dr. Youn on YouTube - ⁠⁠⁠⁠⁠⁠youtube.com/tonyyounmd⁠⁠⁠⁠⁠⁠ Follow Dr. Youn on TikTok - ⁠⁠⁠⁠⁠⁠@doctoryoun⁠⁠⁠⁠⁠⁠ Follow Dr. Youn on Facebook - ⁠⁠⁠⁠⁠⁠@dryoun⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Did you know that hormone healing is directly connected to gut healing? In this episode, I share two stories of patients who improved their PMS and hormone imbalance symptoms by first healing their gut. I'll also break down the best treatments for managing menopause symptoms. Learn the top supplements and diet strategies for PMS, balancing hormones after birth control, and menopause symptoms. Listen now!    Start healing with us! Learn more about our virtual clinic:  https://drruscio.com/virtual-clinic/   Featured products: https://store.drruscio.com/products/elemental-heal  store.drruscio.com/products/healthy-gut-healthy-you https://store.drruscio.com/products/progest-harmony https://store.drruscio.com/products/estro-harmony https://store.drruscio.com/search?q=probiotics https://store.drruscio.com/search?q=adrenal https://store.drruscio.com/search?q=digestive+enzymes